Wu, K.L.

patient myeloma response study thalidomide chromosome treatment arsenic trioxide bortezomib abnormality survival blood disease transplantation therapy dexamethasone br j haematol month analysis toxicity arsenic chemotherapy high-dose trioxide factor response rate myeloma patients marrow cell transplantation chapter cytogenetic ascorbic acid phase effect prognostic deletion high-dose chemotherapy trial group barlogie b sample cancer combination plasma aberration j clin oncol lesion karyotype autologou efficacy progression serum range result disease progression ascorbic chromosomal abnormalities chromosome 13 number prognostic factors m-protein haematol translocation agent plasma cells cycle reduction grade chromosomal outcome barlogie table relapse regimen high-dose therapy diagnosis follow-up randomized melphalan proteasome